Lyra Therapeutics Inc [NASDAQ: LYRA] plunged by -$0.08 during the normal trading session on while it closed the day at $0.20.
Lyra Therapeutics Inc stock has also loss -29.37% of its value over the past 7 days. However, LYRA stock has declined by -31.83% in the 3 months of the year. Over the past six months meanwhile, it has lost -44.44% and lost -96.23% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for LYRA stock reached $12.94 million, with 57.21 million shares outstanding and 56.00 million shares in the current float. Compared to the average trading volume of 999.86K shares, LYRA reached a trading volume of 7422415 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Lyra Therapeutics Inc [LYRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LYRA shares is $0.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LYRA stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Lyra Therapeutics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on May 07, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $2. The new note on the price target was released on May 07, 2024, representing the official price target for Lyra Therapeutics Inc stock.
The Average True Range (ATR) for Lyra Therapeutics Inc is set at 0.02, with the Price to Sales ratio for LYRA stock in the period of the last 12 months amounting to 8.80. The Price to Book ratio for the last quarter was 0.63, with the Price to Cash per share for the same quarter was set at 0.79.
LYRA stock trade performance evaluation
Lyra Therapeutics Inc [LYRA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.37. With this latest performance, LYRA shares dropped by -13.44% in over the last four-week period, additionally sinking by -44.44% over the last 6 months – not to mention a drop of -93.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LYRA stock in for the last two-week period is set at 33.31, with the RSI for the last a single of trading hit 27.39, and the three-weeks RSI is set at 36.25 for Lyra Therapeutics Inc [LYRA]. The present Moving Average for the last 50 days of trading for this stock 0.2563, while it was recorded at 0.2541 for the last single week of trading, and 1.9615 for the last 200 days.
Lyra Therapeutics Inc [LYRA]: An insightful look at the core fundamentals
Lyra Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.64 and a Current Ratio set at 3.64.
Earnings per share (EPS) analysis for Lyra Therapeutics Inc [LYRA] stock
With the latest financial reports released by the company, Lyra Therapeutics Inc posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.32/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LYRA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lyra Therapeutics Inc go to -1.60%.
Lyra Therapeutics Inc [LYRA]: Institutional Ownership
There are presently around $57.98%, or 58.37%% of LYRA stock, in the hands of institutional investors. The top three institutional holders of LYRA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 12.76 million shares, which is approximately 19.9302%. CITADEL ADVISORS LLC, holding 4.77 million shares of the stock with an approximate value of $$1.32 million in LYRA stocks shares; and CITADEL ADVISORS LLC, currently with $$0.78 million in LYRA stock with ownership which is approximately 4.4211%.
